NeuroScientific Biopharmaceuticals Limited (ASX:NSB)

Market Cap	20.62M +145.9%
Revenue (ttm)	317.91K -85.6%
Net Income	-3.18M
EPS	-0.01
Shares Out	332.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	849,557
Open	0.0650
Previous Close	0.0660
Day's Range	0.0620 - 0.0660
52-Week Range	0.0590 - 0.2600
Beta	1.09
Analysts	n/a
Price Target	0.43 (+593.55%)
Earnings Date	Aug 25, 2026

About ASX:NSB

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NSB

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error